MDPI and ACS Style
Kudriavtsev, A.V.; Vakhrusheva, A.V.; Kryuchkov, N.A.; Frolova, M.E.; Blagodatskikh, K.A.; Ivanishin, T.V.; Djonovic, M.; Romanovskaya-Romanko, E.A.; Kovalenko, A.N.; Lioznov, D.A.;
et al. Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. Vaccines 2023, 11, 326.
https://doi.org/10.3390/vaccines11020326
AMA Style
Kudriavtsev AV, Vakhrusheva AV, Kryuchkov NA, Frolova ME, Blagodatskikh KA, Ivanishin TV, Djonovic M, Romanovskaya-Romanko EA, Kovalenko AN, Lioznov DA,
et al. Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. Vaccines. 2023; 11(2):326.
https://doi.org/10.3390/vaccines11020326
Chicago/Turabian Style
Kudriavtsev, Aleksandr V., Anna V. Vakhrusheva, Nickolay A. Kryuchkov, Maria E. Frolova, Konstantin A. Blagodatskikh, Taras V. Ivanishin, Milana Djonovic, Ekaterina A. Romanovskaya-Romanko, Anton N. Kovalenko, Dmitry A. Lioznov,
and et al. 2023. "Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial" Vaccines 11, no. 2: 326.
https://doi.org/10.3390/vaccines11020326
